Clinicians and regulators worry over side effects, particularly the risk of developing a rare neurological condition progressive multifocal leukoencephalopathy (PML), the brain infection that bedevils the -4 integrin antagonist Tysabri (natalizumab), co-marketed by Biogen Idec, of Cambridge, Massachusetts, and Dublin-based Elan.